Moya M. Daniels
No más puestos en curso
Historial de carrera de Moya M. Daniels
Antiguos cargos conocidos de Moya M. Daniels.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
HISTOGEN INC. | Director Técnico/Científico/I+D | 19/10/2020 | 01/08/2021 |
Consejero General | 19/10/2020 | 01/08/2021 | |
OSIRIS THERAPEUTICS, INC. | Corporate Officer/Principal | 01/01/2017 | 01/01/2019 |
ORCHARD THERAPEUTICS PLC | Consejero General | 01/01/2017 | 01/01/2019 |
FATE THERAPEUTICS, INC. | Consejero General | - | 01/07/2017 |
SanBio, Inc.
SanBio, Inc. Medical/Nursing ServicesHealth Services SanBio, Inc. develops regenerative therapies for neurological disorders. The firm is focused on cell therapies for neurological disorders such as stroke, traumatic brain injury, eye disease, and Parkinson's disease. Its product pipeline includes SB623 and SB618. The company was founded by Keita Mori and Toru Kawanishi in 2001 and is headquartered in Mountain View, CA. | Corporate Officer/Principal | - | - |
MACROCURE LTD | Consejero General | - | - |
Formación de Moya M. Daniels.
Saint Augustine's University | Undergraduate Degree |
University of Maryland | Graduate Degree |
Estadísticas
Internacional
Estados Unidos | 7 |
Israel | 2 |
Reino Unido | 2 |
Operativa
General Counsel | 4 |
Corporate Officer/Principal | 2 |
Undergraduate Degree | 1 |
Sectorial
Health Technology | 6 |
Consumer Services | 3 |
Health Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
FATE THERAPEUTICS, INC. | Health Technology |
HISTOGEN INC. | Health Technology |
Empresas privadas | 4 |
---|---|
Macrocure Ltd.
Macrocure Ltd. Medical SpecialtiesHealth Technology Macrocure Ltd. is a clinical-stage biotechnology company, which engages in the development and commercialization of advanced cell therapy products. Its product, CureXcell, is an advanced wound care therapy that treat such wounds by injecting living human white blood cells that have been activate to facilitate the healing process. The company was founded by David Ben-Ami on January 14, 2008 and is headquartered in Petach Tikva, Israel. | Health Technology |
Osiris Therapeutics, Inc.
Osiris Therapeutics, Inc. BiotechnologyHealth Technology Osiris Therapeutics, Inc. engages in the research, development, manufacture, and commercialization of regenerative medicine products. Its biosurgery business focuses on using unique tissue preservation technologies to develop viable human tissue products designed to improve wound closure and surgical outcomes for patients and physicians over standard of care alone. The company was founded by Peter A. Friedli and James S. Burns on December 23, 1992 and is headquartered in Columbia, MD. | Health Technology |
SanBio, Inc.
SanBio, Inc. Medical/Nursing ServicesHealth Services SanBio, Inc. develops regenerative therapies for neurological disorders. The firm is focused on cell therapies for neurological disorders such as stroke, traumatic brain injury, eye disease, and Parkinson's disease. Its product pipeline includes SB623 and SB618. The company was founded by Keita Mori and Toru Kawanishi in 2001 and is headquartered in Mountain View, CA. | Health Services |
Orchard Therapeutics Plc
Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
- Bolsa de valores
- Insiders
- Moya M. Daniels
- Experiencia